Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

Brittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Jorge Cortes, Gautam Borthakur, La Kiesha DeBose, Zhihong Zeng, Heather Schneider, Naveen Pemmaraju, Guillermo Garcia-Manero, Steven Kornblau, William Wierda, Jan Burger, Courtney D. DiNardo, Michael Andreeff, Marina Konopleva, Naval Daver

Research output: Contribution to journalArticle

Abstract

Phosphatidylinositol-3-kinase (PI3K) signaling plays a crucial role in oncogene-mediated tumor growth and proliferation. Buparlisib (BKM120) is an oral pan-class I PI3K inhibitor. This phase I study was conducted to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of BKM120 in patients (pts) with relapsed/refractory acute leukemias. Fourteen pts (12 acute myeloid leukemia, 1 acute lymphoblastic leukemia, and 1 mixed phenotype leukemia) were enrolled. Twelve pts received BKM-120 80 mg/day and two 100 mg/day. The MTD was 80 mg/day. Of the 14 patients treated, the best response was stable disease in one patient that lasted 82 days. The median survival for all patients was 75 days (range 10–568). Three patients with a 3q26 chromosome abnormality had a significantly improved median survival of 360 days (range 278–568) as compared to a median survival of 57 days (range, 10–125) among the 11 other patients. The most frequent drug-related toxicities included confusion, mucositis, dysphagia, and fatigue. Western blot profiling revealed a decrease in p-pS6K/total pS6K in 5/7 (71%) available patient samples with a mean quantitative inhibition of 65% (range, 32–100%) and a decrease in p-FOXO3/total FOXO3 in 4/6 (67%) samples with a mean quantitative inhibition of 93% (range, 89–100%). BKM120 administered at 80 mg/day showed modest efficacy and was tolerable in advanced acute leukemias. Am. J. Hematol. 92:7–11, 2017.

Original languageEnglish (US)
Pages (from-to)7-11
Number of pages5
JournalAmerican Journal of Hematology
Volume92
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
Leukemia
Maximum Tolerated Dose
Class I Phosphatidylinositol 3-Kinases
Survival
NVP-BKM120
Mucositis
Deglutition Disorders
Drug-Related Side Effects and Adverse Reactions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Oncogenes
Acute Myeloid Leukemia
Chromosome Aberrations
Fatigue
Western Blotting
Phenotype

ASJC Scopus subject areas

  • Hematology

Cite this

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. / Ragon, Brittany Knick; Kantarjian, Hagop; Jabbour, Elias; Ravandi, Farhad; Cortes, Jorge; Borthakur, Gautam; DeBose, La Kiesha; Zeng, Zhihong; Schneider, Heather; Pemmaraju, Naveen; Garcia-Manero, Guillermo; Kornblau, Steven; Wierda, William; Burger, Jan; DiNardo, Courtney D.; Andreeff, Michael; Konopleva, Marina; Daver, Naval.

In: American Journal of Hematology, Vol. 92, No. 1, 01.01.2017, p. 7-11.

Research output: Contribution to journalArticle

Ragon, BK, Kantarjian, H, Jabbour, E, Ravandi, F, Cortes, J, Borthakur, G, DeBose, LK, Zeng, Z, Schneider, H, Pemmaraju, N, Garcia-Manero, G, Kornblau, S, Wierda, W, Burger, J, DiNardo, CD, Andreeff, M, Konopleva, M & Daver, N 2017, 'Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias', American Journal of Hematology, vol. 92, no. 1, pp. 7-11. https://doi.org/10.1002/ajh.24568
Ragon, Brittany Knick ; Kantarjian, Hagop ; Jabbour, Elias ; Ravandi, Farhad ; Cortes, Jorge ; Borthakur, Gautam ; DeBose, La Kiesha ; Zeng, Zhihong ; Schneider, Heather ; Pemmaraju, Naveen ; Garcia-Manero, Guillermo ; Kornblau, Steven ; Wierda, William ; Burger, Jan ; DiNardo, Courtney D. ; Andreeff, Michael ; Konopleva, Marina ; Daver, Naval. / Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. In: American Journal of Hematology. 2017 ; Vol. 92, No. 1. pp. 7-11.
@article{4de3373bfcb24d87b6c499df41df78e4,
title = "Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias",
abstract = "Phosphatidylinositol-3-kinase (PI3K) signaling plays a crucial role in oncogene-mediated tumor growth and proliferation. Buparlisib (BKM120) is an oral pan-class I PI3K inhibitor. This phase I study was conducted to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of BKM120 in patients (pts) with relapsed/refractory acute leukemias. Fourteen pts (12 acute myeloid leukemia, 1 acute lymphoblastic leukemia, and 1 mixed phenotype leukemia) were enrolled. Twelve pts received BKM-120 80 mg/day and two 100 mg/day. The MTD was 80 mg/day. Of the 14 patients treated, the best response was stable disease in one patient that lasted 82 days. The median survival for all patients was 75 days (range 10–568). Three patients with a 3q26 chromosome abnormality had a significantly improved median survival of 360 days (range 278–568) as compared to a median survival of 57 days (range, 10–125) among the 11 other patients. The most frequent drug-related toxicities included confusion, mucositis, dysphagia, and fatigue. Western blot profiling revealed a decrease in p-pS6K/total pS6K in 5/7 (71{\%}) available patient samples with a mean quantitative inhibition of 65{\%} (range, 32–100{\%}) and a decrease in p-FOXO3/total FOXO3 in 4/6 (67{\%}) samples with a mean quantitative inhibition of 93{\%} (range, 89–100{\%}). BKM120 administered at 80 mg/day showed modest efficacy and was tolerable in advanced acute leukemias. Am. J. Hematol. 92:7–11, 2017.",
author = "Ragon, {Brittany Knick} and Hagop Kantarjian and Elias Jabbour and Farhad Ravandi and Jorge Cortes and Gautam Borthakur and DeBose, {La Kiesha} and Zhihong Zeng and Heather Schneider and Naveen Pemmaraju and Guillermo Garcia-Manero and Steven Kornblau and William Wierda and Jan Burger and DiNardo, {Courtney D.} and Michael Andreeff and Marina Konopleva and Naval Daver",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/ajh.24568",
language = "English (US)",
volume = "92",
pages = "7--11",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

AU - Ragon, Brittany Knick

AU - Kantarjian, Hagop

AU - Jabbour, Elias

AU - Ravandi, Farhad

AU - Cortes, Jorge

AU - Borthakur, Gautam

AU - DeBose, La Kiesha

AU - Zeng, Zhihong

AU - Schneider, Heather

AU - Pemmaraju, Naveen

AU - Garcia-Manero, Guillermo

AU - Kornblau, Steven

AU - Wierda, William

AU - Burger, Jan

AU - DiNardo, Courtney D.

AU - Andreeff, Michael

AU - Konopleva, Marina

AU - Daver, Naval

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Phosphatidylinositol-3-kinase (PI3K) signaling plays a crucial role in oncogene-mediated tumor growth and proliferation. Buparlisib (BKM120) is an oral pan-class I PI3K inhibitor. This phase I study was conducted to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of BKM120 in patients (pts) with relapsed/refractory acute leukemias. Fourteen pts (12 acute myeloid leukemia, 1 acute lymphoblastic leukemia, and 1 mixed phenotype leukemia) were enrolled. Twelve pts received BKM-120 80 mg/day and two 100 mg/day. The MTD was 80 mg/day. Of the 14 patients treated, the best response was stable disease in one patient that lasted 82 days. The median survival for all patients was 75 days (range 10–568). Three patients with a 3q26 chromosome abnormality had a significantly improved median survival of 360 days (range 278–568) as compared to a median survival of 57 days (range, 10–125) among the 11 other patients. The most frequent drug-related toxicities included confusion, mucositis, dysphagia, and fatigue. Western blot profiling revealed a decrease in p-pS6K/total pS6K in 5/7 (71%) available patient samples with a mean quantitative inhibition of 65% (range, 32–100%) and a decrease in p-FOXO3/total FOXO3 in 4/6 (67%) samples with a mean quantitative inhibition of 93% (range, 89–100%). BKM120 administered at 80 mg/day showed modest efficacy and was tolerable in advanced acute leukemias. Am. J. Hematol. 92:7–11, 2017.

AB - Phosphatidylinositol-3-kinase (PI3K) signaling plays a crucial role in oncogene-mediated tumor growth and proliferation. Buparlisib (BKM120) is an oral pan-class I PI3K inhibitor. This phase I study was conducted to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of BKM120 in patients (pts) with relapsed/refractory acute leukemias. Fourteen pts (12 acute myeloid leukemia, 1 acute lymphoblastic leukemia, and 1 mixed phenotype leukemia) were enrolled. Twelve pts received BKM-120 80 mg/day and two 100 mg/day. The MTD was 80 mg/day. Of the 14 patients treated, the best response was stable disease in one patient that lasted 82 days. The median survival for all patients was 75 days (range 10–568). Three patients with a 3q26 chromosome abnormality had a significantly improved median survival of 360 days (range 278–568) as compared to a median survival of 57 days (range, 10–125) among the 11 other patients. The most frequent drug-related toxicities included confusion, mucositis, dysphagia, and fatigue. Western blot profiling revealed a decrease in p-pS6K/total pS6K in 5/7 (71%) available patient samples with a mean quantitative inhibition of 65% (range, 32–100%) and a decrease in p-FOXO3/total FOXO3 in 4/6 (67%) samples with a mean quantitative inhibition of 93% (range, 89–100%). BKM120 administered at 80 mg/day showed modest efficacy and was tolerable in advanced acute leukemias. Am. J. Hematol. 92:7–11, 2017.

UR - http://www.scopus.com/inward/record.url?scp=85006317938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006317938&partnerID=8YFLogxK

U2 - 10.1002/ajh.24568

DO - 10.1002/ajh.24568

M3 - Article

C2 - 27673440

AN - SCOPUS:85006317938

VL - 92

SP - 7

EP - 11

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -